New clinical trial data for Eli Lilly's 'triple-G' drug, retatrutide, indicates that the medication effectively lowers blood sugar and aids in weight loss. However, the results leave open questions regarding the drug's potential cardiovascular benefits, specifically whether it offers heart protection comparable to other established therapies.